Skip to main
KOD

KOD Stock Forecast & Price Target

KOD Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 29%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Kodiak Sciences Inc. demonstrates a positive outlook due to the consistent efficacy of its product candidate KSI-101, which has shown significant vision gains in treatment-naive subjects, with over 90% of patients achieving retinal dryness by Week 8. The company's pipeline also highlights strong results for tarcocimab, achieving all secondary endpoints and showcasing an 89% decreased risk of sight-threatening complications, which bolsters confidence in its therapeutic potential. Additionally, ongoing pivotal progress and positive feedback from retinal key opinion leaders (KOLs) further enhance the sentiment surrounding Kodiak’s ABC platform and overall growth trajectory.

Bears say

Kodiak Sciences Inc. has faced significant setbacks in its developmental pipeline, highlighted by multiple trial failures, including the Phase 3 GLEAM and GLIMMER trials for diabetic macular edema and the Phase 2b/3 DAZZLE trial for wet AMD. The company reported a substantial net loss of $61.5 million, equating to $1.16 per diluted share for the third quarter of 2025, which raises concerns about its financial viability. Additionally, risks associated with the failure of its product candidates to meet revenue expectations, secure necessary funding, and advance commercialization efforts further contribute to a negative outlook for the stock.

KOD has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 29% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kodiak Sciences Inc (KOD) Forecast

Analysts have given KOD a Buy based on their latest research and market trends.

According to 7 analysts, KOD has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kodiak Sciences Inc (KOD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.